The latest announcement is out from Vivos Therapeutics ( (VVOS) ).
Vivos Therapeutics, Inc. is set to incentivize its workforce and align their interests with those of its stockholders through the newly approved 2024 Omnibus Equity Incentive Plan, which is contingent on stockholder approval. This plan, replacing the 2019 version, will offer options, stock appreciation rights, and other equity-based awards, aiming to boost performance with 1.6 million shares allocated for future awards. Additionally, the company has revamped its executive compensation, enhancing base salaries and potential bonuses for its CEO and CFO, while also outlining severance benefits and restrictive covenants to protect its interests. These changes highlight Vivos Therapeutics’ strategic approach to attracting and retaining top talent while ensuring alignment with long-term company success.
Find detailed analytics on VVOS stock on TipRanks’ Stock Analysis page.
